Lingfu Bio Completes Nearly RMB 100 Million Series A2 Financing to Accelerate Global NHP Resource Expansion and CNS Disease Modeling Platform

Recently, Life Biosciences Co., Ltd. (hereinafter referred to as “Life Biosciences”) completed a Series A2 financing round of nearly RMB 100 million. The lead investor was SDIC Venture Capital, with follow-on investments from Hainan Rongzhi Talent Innovation and Venture Capital Fund Partnership (Limited Partnership) and Sanya Yazhouwan Venture Capital Co., Ltd. Previously, the company had completed its angel round, a Pre-A round exceeding RMB 200 million, and a Series A1 round of RMB 170 million. Investors included China Life Equity Investment, Legend Capital, Hainan Rongzhi Talent Innovation and Venture Capital Fund Partnership (Limited Partnership), Sanya Yazhouwan Venture Capital Co., Ltd., Matrix Partners China, Puhua Capital, Cyagen Biosciences, Changfazhan, and several entrepreneurs in the laboratory animal industry.

The proceeds from the company’s financing will be primarily allocated to the domestic and international layout of non-human primate (NHP) resource bases, as well as the construction of experimental facilities related to brain science and nervous system disease models. This financing will support Life Biosciences in continuously enhancing its high-quality laboratory animal resources and the industrial chain layout of high-value-added model technologies, thereby achieving a complete closed loop encompassing NHP resources, disease models, and experimental service capabilities.

Life Biosciences is a research service provider dedicated to integrating three core pillars: the full industry chain of laboratory animal resources, the full industry chain of animal model technologies, and high-value-added innovative scientific research services. The company serves innovative pharmaceutical enterprises and large CRO clients by establishing a high-standard, scaled platform for the supply of laboratory animals. It supports the development of drug targets originating from source innovation, as well as the screening and validation of drug molecules, by building a development platform for complex disease animal models. Furthermore, it serves scientists, clinicians, and innovative drug R&D enterprises by establishing scientific research service centers in core regions. Meanwhile, Life Biosciences operates as an open collaboration platform, actively promoting industry consolidation and participating in national strategic reserve safeguards. By collaborating on major projects with the Ministry of Science and Technology and biological infrastructure initiatives under the Ministry of Agriculture, and through its professional operational and technical services, the company has become a key project supported by national and local governments. It also provides strategic supply guarantees of basic laboratory animals and model animals for critical needs such as the development of drugs against major infectious diseases.

Life Biosciences focuses on the development of non-human primate (NHP) experimental research, operating one of the few integrated service platforms in China that combines NHP research services with central nervous system (CNS) disease modeling. The company is capable of establishing dozens of types of NHP disease models, including those for Parkinson’s disease, stroke, cerebral ischemia, epilepsy, depression, and amyotrophic lateral sclerosis (ALS). Life Biosciences has established extensive collaborative partnerships with leading innovative pharmaceutical companies and research institutions both domestically and internationally.

Life BiosciencesCEOMs. Zhang Lei stated:The growth of Life Biosciences has been inseparable from the support of investors and industry partners. The successful completion of this Series A2 financing round demonstrates investor confidence in Life Biosciences, led by SDIC Venture Capital Co., Ltd. Life Biosciences has been committed to building a high-quality industrial chain encompassing laboratory animal resources and high-value-added model-based experimental services. In particular, the company has established end-to-end capabilities in brain science and neuroscience, ranging from animal resource provision and custom model development to scientific research services. Moving forward, we will focus on developing medium- and large-sized disease animal models that address significant unmet needs in innovative drug R&D—areas where small laboratory animals are inadequate or ineffective—and hold substantial significance for clinical translation. By collaborating extensively with more experts and partners across the industry, we aim to build an open-resource and experimental platform to foster innovative development in the biopharmaceutical sector.

SDIC Venture Capital stated:The laboratory animal and model organism industry provides critical support for deciphering the laws of life, disease treatment, pharmaceutical R&D, and animal breeding. As a strategic, resource-based foundational platform for biomedicine, achieving self-sufficiency and import substitution in laboratory animals holds significant strategic importance. It requires the effective integration of national policies, industrial support, and capital market resources to rapidly build core competitiveness. The establishment of a globalized, high-standard system for such platforms determines the level of China’s biomedical innovation and its global competitiveness.Life Biosciences has largely completed its layout of large animal resources, established a high-standard laboratory animal system, created certain industry barriers, and secured a leading advantage in the industrial chain. It has officially risen to become one of the few domestic full-chain suppliers that simultaneously possess comprehensive large animal resources and leading scientific research service capabilities. Investing in Life Biosciences represents a key strategic move by SDIC Venture Capital Co., Ltd. to build a biomedical innovation ecosystem. Aligning with our investment strategy of “serving national innovation strategies and focusing on the commercialization of scientific and technological achievements,” we support Life Biosciences in establishing a one-stop, international, and professional service platform for laboratory and model animals. This initiative aims to promote industry consolidation and build a bridge between original innovative drug development and industrial translation, thereby better facilitating the transformation of original biomedical innovations in China and globally.

SDIC Venture Capital, established in 2016, is a venture capital fund management company specially set up by China State Development & Investment Corp. (SDIC) on a market-oriented basis. It was created to implement the national innovation-driven development strategy, deepen comprehensive strategic cooperation with the Ministry of Science and Technology, and accelerate the transfer and commercialization of national scientific and technological achievements. Through platforms such as the National Science and Technology Major Project Achievement Transformation Fund, the SDIC Beijing-Tianjin-Hebei Scientific and Technological Achievement Transformation Fund, the SDIC High-Tech (Shenzhen) Venture Capital Fund, the SDIC (Ningbo) Scientific and Technological Achievement Transformation Fund, and the SDIC Greater Bay Area Scientific and Technological Achievement Transformation Fund, SDIC Venture Capital consistently focuses on investment goals related to the transformation of scientific and technological achievements. It targets key sectors including advanced manufacturing, electronic information, biomedicine, and materials and energy, while aligning with national regional development strategies such as the Beijing-Tianjin-Hebei region, the Yangtze River Delta, and the Guangdong-Hong Kong-Macao Greater Bay Area. The company continues to promote breakthroughs in independent innovation of core key technologies and build a robust investment ecosystem for the transformation of scientific and technological achievements.

Life Biosciences is a research service provider that integrates three core pillars: the full industry chain of laboratory animal resources, the full industry chain of laboratory animal model technologies, and high-value-added innovative scientific research services. Its subsidiary, Jiangsu Life Zhaoshengyuan, is a leading provider of laboratory dogs and marmosets in China; Chengdu Life Shiye specializes in supplying non-human primates with unique characteristics; Shenzhen Life Top and Beijing Shouke Life are professional providers of laboratory animal models and animal-based research services; and Beijing Renyuan Xinsheng is an innovation platform based on molecular and cell biology techniques and animal gene editing technologies. Together, they provide full-industry-chain scientific research services for the laboratory animal sector, empowering innovation in life sciences.

“Hosted by Life BiosciencesHigh-Level Summit on the Development of Brain Science and Neuroscience and the Creation and Application of Related Animal Models“(April 14, Beijing), bringing together numerous internationally renowned experts from Beijing, Shanghai, Guangzhou, and Shenzhen, as well as innovative pharmaceutical companies and investment institutions. Attend in person—click to register now!”